Published in Biomed Res Int on May 27, 2014
Angiotensin II Blockade for Chronic Allograft Nephropathy | NCT00067990
Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury. Pediatr Nephrol (2014) 0.94
Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics Approach. Sci Rep (2017) 0.75
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46
TGF-beta and epithelial-to-mesenchymal transitions. Oncogene (2005) 10.02
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest (2001) 4.92
Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest (2003) 4.58
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (1992) 3.96
Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev (1997) 3.86
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int (1999) 3.09
The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int (1996) 2.97
TGF-beta in renal injury and disease. Semin Nephrol (2007) 2.65
Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol (2010) 2.55
Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol (2002) 2.51
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J (2003) 2.15
Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant (2012) 2.10
The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 2.02
The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int (2005) 2.02
HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int (2006) 1.85
Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol (2003) 1.83
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2007) 1.80
The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation (2002) 1.72
Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int (2000) 1.72
Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int (2001) 1.70
The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation (1994) 1.69
Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol (2004) 1.64
Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci U S A (1991) 1.64
A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest (2010) 1.61
Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol (2002) 1.52
Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol (2006) 1.43
Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol (1999) 1.37
Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int (2002) 1.37
Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol Renal Physiol (2007) 1.33
Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant (2006) 1.29
New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys (2002) 1.26
Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int (1996) 1.20
Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis (2005) 1.19
Chronic allograft nephropathy: An update. Kidney Int (1999) 1.19
CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol (2008) 1.19
13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol (2005) 1.17
Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol (2007) 1.17
Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant (2006) 1.14
Epithelial-to-mesenchymal transition and oxidative stress in chronic allograft nephropathy. Am J Transplant (2005) 1.13
Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation (2003) 1.11
Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney Int (1985) 1.09
Chronic allograft nephropathy. Curr Opin Nephrol Hypertens (2005) 1.09
Chronic allograft nephropathy: intraepithelial signals generated by transforming growth factor-beta and bone morphogenetic protein-7. Am J Transplant (2006) 1.08
Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant (2010) 1.07
Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol (2003) 1.07
Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol (2012) 1.05
Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One (2009) 1.03
Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol (2001) 1.03
Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant (2002) 1.02
Chronic rejection of mouse kidney allografts. Kidney Int (1999) 1.02
Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J Cardiovasc Pharmacol (2007) 1.02
Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant (2007) 1.02
Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6 months. Nephrol Dial Transplant (2009) 1.00
HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci (2008) 0.99
Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. J Am Soc Nephrol (1997) 0.98
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens (2006) 0.98
Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med (2003) 0.98
Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation (1999) 0.98
Prolyl 4-hydroxylase and its role in collagen synthesis. J Hepatol (1991) 0.97
Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension (2001) 0.97
Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int (2002) 0.97
The relaxin gene-knockout mouse: a model of progressive fibrosis. Ann N Y Acad Sci (2005) 0.97
Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant (2006) 0.97
Senescence of renal cells: molecular basis and clinical implications. Nephrol Dial Transplant (2003) 0.95
A frequent pathway to glomerulosclerosis: deterioration of tuft architecture-podocyte damage-segmental sclerosis. Kidney Blood Press Res (1996) 0.95
Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant (2007) 0.94
Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc (2008) 0.93
Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-β signaling pathways. J Cell Sci (2013) 0.93
Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation (2003) 0.93
Predictors of renal transplant histology at three months. Transplantation (1999) 0.93
Pathophysiology and treatment options of chronic renal allograft damage. Nephrol Dial Transplant (2013) 0.92
Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplant Rev (Orlando) (2012) 0.91
PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol (2003) 0.90
Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation (2009) 0.90
The value of electron microscopy in the diagnosis of chronic renal allograft rejection. Mod Pathol (2001) 0.90
Factors influencing long-term outcomes following renal transplantation: a review. JNMA J Nepal Med Assoc (2008) 0.89
The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design. Nephrol Dial Transplant (2007) 0.89
Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis. Am J Nephrol (1997) 0.89
Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation (2005) 0.88
Predictors of renal allograft histologic damage progression. J Am Soc Nephrol (2005) 0.88
Quality of life following live donor renal transplantation: a single centre experience. Ann Transplant (2010) 0.88
Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation (2005) 0.87
Inhibition of nuclear factor-kappaB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. Kidney Int (2003) 0.87
A randomized double-blind trial of the use of human recombinant superoxide dismutase in renal transplantation. Transplantation (1993) 0.87
Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s. Ann Surg (1991) 0.87
Telomere length of recipients and living kidney donors and chronic graft dysfunction in kidney transplants. Transplantation (2014) 0.86
Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int (1999) 0.85
Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Int (2010) 0.85
Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chem Biol Interact (2010) 0.84
Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. Am J Transplant (2003) 0.83
A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation (2009) 0.83
Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program. J Nephropathol (2014) 0.82
Impact of genetic polymorphisms of the renin-angiotensin system and of non-genetic factors on kidney transplant function--a single-center experience. Clin Transplant (2009) 0.82
High transforming growth factor-beta and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection. Transplantation (2002) 0.81